Berberine Ameliorates Atrial Remodeling and Inhibits the Atrial Fibrillation of Mice via Regulating NLRP3 Inflammasome
Phytotherapy Research · 2025
DOI: 10.1002/ptr.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2025. Verfasst von Na An und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Berberine, NLR Family, Pyrin Domain-Containing 3 Protein, Atrial Fibrillation, Inflammasomes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the CACMS Innovation Fund, the China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Increased cardiomyocyte‐specific activation of the NLRP3 inflammasome contributes to the development of atrial fibrillation (AF). Berberine (BBR) exhibits numerous beneficial effects on the cardiovascular system. This study investigated how the NLRP3 inflammasome regulates susceptibility to hypertension‐induced AF and the effects of BBR on this susceptibility. Blood pressure was monitored in mice using a tail pressure sensor device. AF was induced by burst stimulation of the esophagus. The target proteins of BBR were screened by network pharmacology, and molecular docking was performed. The changes in atrial tissue structure were observed by pathological tissue staining and transmission electron microscopy. Western blot analysis was used for protein verification. Intracellular Ca 2+ release was detected by confocal laser microscopy and the IonOptix system. We found that in angiotensin II (Ang II)‐induced AF, NLRP3 inflammasome activation was inhibited, ultimately inhibiting hypertensive AF susceptibility. In a recombinant adeno‐associated virus 9 (rAAV9)‐NLRP3 overexpression model, BBR mitigated the increase in systolic blood pressure and the development and progression of AF by inhibiting the NLRP3 inflammasome. This study provides hitherto undocumented evidence that the NLRP3 inflammasome acts as a critical regulator in the progression of Ang II‐induced AF and that BBR may serve as a viable treatment for AF by inhibiting NLRP3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Key Laboratory of Chinese Internal Medicine of Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.
- Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China.
- Department of Cardiology, Beijing AnZhen Hospital of the Capital University of Medical Sciences, Beijing, China.
- Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
ORCID-Profile: Na An
Förderung
- National Natural Science Foundation of China
- the CACMS Innovation Fund
- the China Postdoctoral Science Foundation
- the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
Zitieren
APA
An, N., Yang, F., Liu, N., Gao, Y., Shang, H., & Xing, Y. (2025). Berberine Ameliorates Atrial Remodeling and Inhibits the Atrial Fibrillation of Mice via Regulating NLRP3 Inflammasome. Phytotherapy Research. https://doi.org/10.1002/ptr.70011
Vancouver
An N, Yang F, Liu N, Gao Y, Shang H, Xing Y. Berberine Ameliorates Atrial Remodeling and Inhibits the Atrial Fibrillation of Mice via Regulating NLRP3 Inflammasome. Phytotherapy Research. 2025. doi:10.1002/ptr.70011
BibTeX
@article{An2025,
author = {An, Na and Yang, Fan and Liu, Nian and Gao, Yonghong and Shang, Hongcai and Xing, Yanwei},
title = {Berberine Ameliorates Atrial Remodeling and Inhibits the Atrial Fibrillation of Mice via Regulating NLRP3 Inflammasome},
journal = {Phytotherapy Research},
year = {2025},
doi = {10.1002/ptr.70011}
}
EUVIMED